Earnings ·
Mirum Reports Q3 Net Sales of $185.7M and Raises 2026 Guidance to $715-$720M
MIRMMirum Pharmaceuticals, Inc.
Mirum Pharmaceuticals reported third-quarter net product sales of $185.7 million, up from $133.0 million in the prior-year period, driven by strong growth in LIVMARLI and Bile Acid Medicines. The company raised its full-year 2026 net product sales guidance to a range of $715 million to $720 million. Mirum also announced U.S. FDA approval and launch of ATEBRIOZ for fibrodysplasia ossificans progressiva, positive Phase 3 results for LIVMARLI in rare cholestatic diseases, and positive Phase 3 data for brelovitug in chronic hepatitis delta virus. Operating expenses totaled $245.5 million due to increased R&D spending and non-recurring acquired in-process research and development charges of $13.5 million. The company repurchased $20.0 million of convertible notes and ended the quarter with $500.5 million in unrestricted cash, cash equivalents, and investments. Mirum Pharmaceuticals is a rare disease company focused on developing and commercializing medicines for liver and genetic diseases.